| PREDICEN - PREDISCAN
TESTING BEFORE TREATING
ABOUT US
At PREDICEN, we bridge the gap between clinical research and patient care. We are developing PREDISCAN, a cutting-edge, in-hospital integrated platform designed to analyze patient-derived organoids (PDOs)- true avatars of each patient's tumor.
​
By enabling oncology teams to simulate and assess therapeutic responses in a controlled environment before clinical administration, PREDISCAN will support more precise, personalized, and data-driven treatment decisions.​​​​
​
"We don't just predict the future of medicine :
we build it, one patient at a time."
OUR MISSION
By combining real-world data with functional precision medicine, PREDICEN is redefining how cancer is treated :
​
-
Reducing unnecessary toxicity by ruling out ineffective therapies early
-
Increasing treatment success through smarter, data-driven decisions
-
Bridging research and care to accelerate innovation at the point of care
​
10+
Years of Scientific Expertise
4x
Lower Therapeutic Failure
100 %
Negative Predictive Value
OUR TECHNOLOGIES
Patient-Derived Tumoroids (PDO)
High-Fidelity Clinical Modeling
We leverage Patient-Derived Organoids (PDOs) as high-fidelity biological avatars to predict therapeutic outcomes with unprecedented precision.
This model demonstrates an 88% accuracy in predicting treatment efficacy and a 100% negative predictive value (1), ensuring no patient is subjected to ineffective, toxic treatments.
​
As validated in seminal research (2,3), PDOs effectively mirror intra-tumor heterogeneity and metastatic response, bridging the gap between in vitro testing and in vivo reality.
​
(1) : Vlachogiannis et al., Science 2018
(2) : Gambara et al., Front. Pharmacol. 2018
(3) : Cesana et al, Cell. Death. Discovery 2026
Holographic Microscope
Next-Generation Holographic Imaging
​By combining speed, simplicity, and reliability, our holographic microscopy solution is ideal for high-throughput hospital environments and real-world clinical use.
​
-
Label-free technology – preserves cell viability by eliminating the need for toxic stains
-
Instant 3D visualization – capture comprehensive 2D and 3D data in a single frame, with no need for Z-stacks
-
Unmatched speed – obtain a full field of view in minutes, not hours
-
Clinical-grade robustness – built for demanding hospital workflows and real-world applications
-
Ease of use – intuitive and accessible, with no advanced technical skills required
AI-Powered Analytics
Advanced AI & Instance Segmentation​
​
At the heart of our platform is a native AI engine, specifically trained for organoid recognition. It automates the complex task of monitoring growth and morphological changes with surgical precision, turning raw imaging data into actionable insights.
​
-
Automated Tracking – Continuously monitor and compare individual organoids over time for dynamic, longitudinal analysis.
-
Instance Segmentation – Accurately identify and isolate every cellular object within a sample, ensuring precise measurements.
-
Data-Driven Insights – Transform complex visual data into meaningful metrics, accelerating decision-making in research and clinical applications.
OUR TEAM
Our team brings together experts in oncology, biotechnology, and clinical research.
We are driven by a shared passion for innovation and medical advancement, where every member plays a vital role in bringing our vision to life.
OPERATIONAL TEAM
STRATEGIC TEAM
OUR PARTNERS
CONTACT US
ADRESS
5 Av du Grand Sablon
Bâtiment Biopolis
38700 La Tronche
France
Téléphone
+33 4 76 54 95 18